More recently established treatments for RVO have taken a giant leap forward from laser photocoagulation since intravitreally ...
Vabysmo now covered across all three approved indications in the province, providing patients with a comprehensively funded option for their needs "This expansion in coverage for people with RVO in ...
The results of a phase 1b study that evaluated a potential new treatment for macular edema associated with inflammation, ...
TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...
EYLEA HD led to improved vision with extended dosing intervals, achieving non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed every 4 ...
September 21, 2012 — The US Food and Drug Administration (FDA) has approved aflibercept injection (Eylea, Regeneron Pharmaceuticals) for treating macular edema following central retinal vein occlusion ...
An injection of stem cells into the eye may soon slow or reverse the effects of early-stage age-related macular degeneration, according to new research from scientists at Cedars-Sinai. Currently, ...
WALTHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that eight abstracts were accepted for oral presentations at the 49 th Macula Society ...
Patients with dry age-related macular degeneration treated with recently approved intravitreal pegcetacoplan (Syfovre) injections developed "floaters" from presumed intravitreal silicone oil droplets ...
Long-term data and subgroup analyses from pivotal EYLEA HD clinical program highlight durability of visual improvements and consistent safety across extended dosing intervals and patient ...
CHICAGO — The number of injections required for the successful treatment of neovascular age-related macular degeneration could be reduced considerably with experimental therapies, new research shows.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results